Discover 3,059 paid clinical trials in Cambridge, Massachusetts. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 3,059
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
for
Squamous Cell Carcinoma of Head and Neck
Location: Boston MA, Hartford CT, New Haven CT, Mineola NY,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT07276399
Phase 3, Recruiting
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
for
Advanced Solid Tumor
Location: Boston MA, Montreal, Toronto, Pittsburgh PA,
Sponsor: Senhwa Biosciences, Inc.
Sex: All
Age: 18+
Code: NCT04890613
Phase 1, Recruiting
Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes
for
Genetic Testing, BRCA1/2
Location: Boston MA, Commack NY, Harrison NY, Uniondale NY,
Sponsor: Memorial Sloan Kettering Cancer Center
Sex: Female
Age: 25+
Code: NCT03396341
Recruiting
Statins and Breast Cancer Biomarkers
for
Breast Cancer
Location: Boston MA, Burlington VT, Newark DE, Goldsboro NC,
Sponsor: University of Vermont
Sex: Female
Age: 35 - 55
Code: NCT00914017
Phase 2, Recruiting
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
for
Myasthenia Gravis
Location: Foxborough MA, Farmington CT, New York NY, Raleigh NC,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18 - 70+
Code: NCT07217587
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Location: Boston MA, Providence RI, New York NY, Durham NC,
Sponsor: Context Therapeutics Inc.
Sex: All
Age: 18+
Code: NCT06515613
Phase 1, Recruiting
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
for
Monoclonal Gammopathy of Undetermined Significance (MGUS),
Location: Boston MA, Stony Brook NY, New York NY, Philadelphia PA,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06140524
Phase 2, Recruiting
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors